Add time:09/26/2019         Source:sciencedirect.com

PurposeA single-entity, once-daily, extended-release formulation of HYDROCODONE (cas 125-29-1) bitartrate (HYD) has been developed for the management of moderate to severe chronic pain. Hydrocodone undergoes cytochrome P-450 (CYP)-mediated metabolism involving the CYP3A4 and CYP2D6 isozymes. CYP3A4 yields norhydrocodone, a major inactive metabolite, whereas CYP2D6 yields hydromorphone, a minor active metabolite. This study examined the influence of the coadministration of paroxetine, a strong selective CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone (and hydromorphone) in healthy adults.

We also recommend Trading Suppliers and Manufacturers of HYDROCODONE (cas 125-29-1). Pls Click Website Link as below: cas 125-29-1 suppliers